Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sacituzumab tirumotecan - Klus Pharma/Merck & Co

Next Previous
X
Search
Drug Profile

Sacituzumab tirumotecan - Klus Pharma/Merck & Co

Alternative Names: MK-2870; sac-TMT; SKB-264

Latest Information Update: 06 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Klus Pharma
  • Developer Klus Pharma; Merck & Co; Sichuan Kelun-Biotech Biopharmaceutical
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Triple negative breast cancer
  • Preregistration Non-small cell lung cancer
  • Phase III Adenocarcinoma; Cervical cancer; Endometrial cancer; HER2 negative breast cancer
  • Phase II Biliary cancer; Cancer; Colorectal cancer; Pancreatic cancer; Solid tumours
  • Phase I/II Gastrointestinal cancer; Urogenital cancer

Most Recent Events

  • 04 Dec 2024 Sacituzumab tirumotecan - Klus Pharma/Merck & Co receives Breakthrough Therapy status for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
  • 27 Nov 2024 Launched for Triple-negative-breast-cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) - First global launch
  • 27 Nov 2024 Registered for Triple-negative-breast-cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) - First global approval

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top